80 related articles for article (PubMed ID: 15736447)
41. Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin A on the energy metabolism of breast cancer cells.
Rodrigues MF; Carvalho É; Pezzuto P; Rumjanek FD; Amoêdo ND
J Cell Biochem; 2015 May; 116(5):797-808. PubMed ID: 25510910
[TBL] [Abstract][Full Text] [Related]
42. Morphological effects of natural retinoids on human mammary carcinoma cell lines in monolayer culture.
Wetherall NT; Reiss T; Parmenter M; Halter SA
Scan Electron Microsc; 1982; (Pt 4):1565-75. PubMed ID: 7184138
[TBL] [Abstract][Full Text] [Related]
43. Basis for the anti-tumor and chemopreventive activities of glucarate and the glucarate:retinoid combination.
Abou-Issa H; Dwivedi C; Curley RW; Kirkpatrick R; Koolemans-Beynen A; Engineer FN; Humphries KA; el-Masry W; Webb TE
Anticancer Res; 1993; 13(2):395-9. PubMed ID: 8517653
[TBL] [Abstract][Full Text] [Related]
44. Enhancing the anti-angiogenic action of histone deacetylase inhibitors.
Kuljaca S; Liu T; Tee AE; Haber M; Norris MD; Dwarte T; Marshall GM
Mol Cancer; 2007 Oct; 6():68. PubMed ID: 17958916
[TBL] [Abstract][Full Text] [Related]
45. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Gediya LK; Belosay A; Khandelwal A; Purushottamachar P; Njar VC
Bioorg Med Chem; 2008 Mar; 16(6):3352-60. PubMed ID: 18166465
[TBL] [Abstract][Full Text] [Related]
46. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
Urbinati G; Marsaud V; Plassat V; Fattal E; Lesieur S; Renoir JM
Int J Pharm; 2010 Sep; 397(1-2):184-93. PubMed ID: 20603204
[TBL] [Abstract][Full Text] [Related]
47. Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines.
Sponziello M; Scipioni A; Durante C; Verrienti A; Maranghi M; Giacomelli L; Ferretti E; Celano M; Filetti S; Russo D
J Endocrinol Invest; 2010 Jan; 33(1):2-6. PubMed ID: 19794300
[TBL] [Abstract][Full Text] [Related]
48. HDAC inhibitors show benefits in breast cancer.
Rose S
Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586693
[TBL] [Abstract][Full Text] [Related]
49. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Hahn CK; Ross KN; Warrington IM; Mazitschek R; Kanegai CM; Wright RD; Kung AL; Golub TR; Stegmaier K
Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9751-6. PubMed ID: 18607002
[TBL] [Abstract][Full Text] [Related]
50. The synergistic apoptotic effects of thiophenfurin, an inosine monophosphate dehydrogenase inhibitor, in combination with retinoids in HL60 cells.
Meli M; Tolomeo M; Grifantini M; Franchetti P; Cappellacci L; Simoni D; Invidiata FP; Aiello S; Dusonchet L
Oncol Rep; 2007 Jan; 17(1):185-92. PubMed ID: 17143497
[TBL] [Abstract][Full Text] [Related]
51. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Coffey DC; Kutko MC; Glick RD; Swendeman SL; Butler L; Rifkind R; Marks PA; Richon VM; LaQuaglia MP
Med Pediatr Oncol; 2000 Dec; 35(6):577-81. PubMed ID: 11107121
[TBL] [Abstract][Full Text] [Related]
52. Proteomic analysis of changes in the protein composition of MCF-7 human breast cancer cells induced by all-trans retinoic acid, 9-cis retinoic acid, and their combination.
Flodrova D; Benkovska D; Macejova D; Bialesova L; Hunakova L; Brtko J; Bobalova J
Toxicol Lett; 2015 Jan; 232(1):226-32. PubMed ID: 25455455
[TBL] [Abstract][Full Text] [Related]
53. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.
Gore SD; Carducci MA
Expert Opin Investig Drugs; 2000 Dec; 9(12):2923-34. PubMed ID: 11093362
[TBL] [Abstract][Full Text] [Related]
54. Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules.
Margheri M; Pacini N; Tani A; Nosi D; Squecco R; Dama A; Masala E; Francini F; Zecchi-Orlandini S; Formigli L
Eur J Pharmacol; 2012 Apr; 681(1-3):34-43. PubMed ID: 22532966
[TBL] [Abstract][Full Text] [Related]
55. Differential Potentiation of Retinoic Acid Effects against Human Breast Cancer Cells by Unsaturated Fatty Acids.
Quiroga PL; Soria EA; Valentich MA; Eynard AR
Nutr Cancer; 2018 Oct; 70(7):1137-1144. PubMed ID: 30216095
[TBL] [Abstract][Full Text] [Related]
56. Phase 2 study of sodium phenylbutyrate in ALS.
Cudkowicz ME; Andres PL; Macdonald SA; Bedlack RS; Choudry R; Brown RH; Zhang H; Schoenfeld DA; Shefner J; Matson S; Matson WR; Ferrante RJ;
Amyotroph Lateral Scler; 2009 Apr; 10(2):99-106. PubMed ID: 18688762
[TBL] [Abstract][Full Text] [Related]
57. The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors.
Perera N; Hergovich A
Chin Clin Oncol; 2017 Feb; 6(1):9. PubMed ID: 28249539
[No Abstract] [Full Text] [Related]
58. Augmented Therapeutic Potential of EC-Synthetic Retinoids in Caco-2 Cancer Cells Using an In Vitro Approach.
Abdelaal MR; Ibrahim E; Elnagar MR; Soror SH; Haffez H
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012706
[TBL] [Abstract][Full Text] [Related]
59. Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE-independent mechanisms of gene expression.
Coyle KM; Maxwell S; Thomas ML; Marcato P
Sci Rep; 2017 Nov; 7(1):16684. PubMed ID: 29192143
[TBL] [Abstract][Full Text] [Related]
60. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment.
Tavares TS; Nanus D; Yang XJ; Gudas LJ
Cancer Biol Ther; 2008 Oct; 7(10):1607-18. PubMed ID: 18769122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
